-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, VantAI and Boehringer Ingelheim jointly announced that they have entered into an early drug discovery research collaboration focused on the discovery of innovative degraders that degrade traditional "undruggable" targets
VantAI, a subsidiary of Roivant Sciences, uses machine learning to design and optimize induced proximity drugs
The company's evolutionary scoring system draws on naturally occurring protein-protein interaction interfaces, allowing generative models to design molecular glues with smaller molecular weights to form highly cooperative ternary complexes
"We are very excited to collaborate with Boehringer Ingelheim in the field of induced proximity, specifically targeting 'non-druggable' disease targets
Boehringer Ingelheim will provide VantAI with undisclosed upfront payments and preclinical, clinical and commercial milestone payments
References:
References:[1] VantAI Forms Research Collaboration with Boehringer Ingelheim to Identify Novel Protein Degraders.
[1] VantAI Forms Research Collaboration with Boehringer Ingelheim to Identify Novel Protein Degraders.
Retrieved April 21, 2022, from https:// -Forms-Research-Collaboration-with-Boehringer-Ingelheim-to-Identify-Novel-Protein-Degraders.
html